ABSI
NASDAQ · Biotechnology
Absci Corp
$9.93
-0.78 (-7.28%)
Financial Highlights (FY 2026)
Revenue
3.49M
Net Income
-143,318,107
Gross Margin
—
Profit Margin
-4,113.7%
Rev Growth
-21.3%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -4,297.0% | -3,867.3% | -17.8% | -17.1% |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% | -17.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.49M | 4.43M | 58.57M | 57.07M |
| Gross Profit | — | — | 34.21M | 33.33M |
| Operating Income | -149,920,330 | -171,511,754 | -10,406,862 | -9,769,969 |
| Net Income | -143,318,107 | -163,958,683 | -8,944,093 | -9,875,873 |
| Gross Margin | — | — | 58.4% | 58.4% |
| Operating Margin | -4,297.0% | -3,867.3% | -17.8% | -17.1% |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% | -17.3% |
| Rev Growth | -21.3% | -21.3% | +10.3% | +2.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.76M | 3.76M | 100.48M | 118.62M |
| Total Equity | 817.41M | 817.41M | 298.85M | 311.81M |
| D/E Ratio | 0.00 | 0.00 | 0.34 | 0.38 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -135,097,866 | -163,140,933 | -15,160,350 | -13,058,914 |
| Free Cash Flow | — | — | -10,726,027 | -11,756,277 |